JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Arvinas Inc

Abierto

SectorSalud

7.58 1.34

Resumen

Variación precio

24h

Actual

Mínimo

7.37

Máximo

7.82

Métricas clave

By Trading Economics

Ingresos

128M

83M

Ventas

130M

189M

BPA

1.14

Margen de beneficio

43.909

Empleados

430

EBITDA

129M

73M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+130.86% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-61M

572M

Apertura anterior

6.24

Cierre anterior

7.58

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

175 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Arvinas Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 may 2025, 18:41 UTC

Principales Movimientos del Mercado

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

Comparación entre iguales

Cambio de precio

Arvinas Inc Esperado

Precio Objetivo

By TipRanks

130.86% repunte

Estimación a 12 meses

Media 17.13 USD  130.86%

Máximo 24 USD

Mínimo 11 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arvinas Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

7

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.55 / 9.11Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

175 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.